{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:19:12Z","timestamp":1773983952472,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004861","name":"Mackay Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tjog.2025.05.015","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:17:47Z","timestamp":1757513867000},"page":"796-801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["KELIM score and BRCA status are unreliable to predict the completeness of cytoreduction during interval debulking surgery with hyperthermic intraperitoneal chemotherapy for ovarian cancers"],"prefix":"10.1016","volume":"64","author":[{"given":"Yu-Min","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Syun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Li","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Chien","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kung-Liahng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Ruei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tjog.2025.05.015_bib1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.tjog.2025.05.015_bib2","series-title":"Cancer registry annual report in Taiwan in 2021","year":"2023"},{"issue":"2","key":"10.1016\/j.tjog.2025.05.015_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.tjog.2025.05.015_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17103523","article-title":"Outcomes in advanced stage epithelial ovarian, fallopian tubal, and peritoneal cancer after primary surgery and adjuvant chemotherapies: a single-institute real-world experience","volume":"17","author":"Chang","year":"2020","journal-title":"Int J Environ Res Publ Health"},{"issue":"3","key":"10.1016\/j.tjog.2025.05.015_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tjog.2025.05.015_bib6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.tjog.2025.05.015_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100586","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials","volume":"7","author":"Filis","year":"2022","journal-title":"ESMO Open"},{"issue":"23","key":"10.1016\/j.tjog.2025.05.015_bib8","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK Team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.tjog.2025.05.015_bib9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"17","key":"10.1016\/j.tjog.2025.05.015_bib10","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.tjog.2025.05.015_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.18632\/oncotarget.12306","article-title":"Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.tjog.2025.05.015_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/IGC.0000000000000327","article-title":"Prognostic significance of Sugarbaker's peritoneal cancer index for the operability of ovarian carcinoma","volume":"25","author":"Lampe","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2025.05.015_bib13","series-title":"R: A language and environment for statistical computing","year":"2021"},{"key":"10.1016\/j.tjog.2025.05.015_bib14","article-title":"survminer: Drawing Survival Curves using \u2018ggplot2\u2019","author":"Kassambara","year":"2021","journal-title":"R package version 0.4.9;"},{"issue":"13","key":"10.1016\/j.tjog.2025.05.015_bib15","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.tjog.2025.05.015_bib16","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2b","key":"10.1016\/j.tjog.2025.05.015_bib17","first-page":"1329","article-title":"Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy","volume":"22","author":"Panteix","year":"2002","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.tjog.2025.05.015_bib18","first-page":"550","article-title":"Hyperthermia as an immunotherapy strategy for cancer","volume":"10","author":"Skitzki","year":"2009","journal-title":"Curr Opin Invest Drugs"},{"issue":"6","key":"10.1016\/j.tjog.2025.05.015_bib19","article-title":"Past, present, and future of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"13","author":"Mishra","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.tjog.2025.05.015_bib20","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.tjog.2025.05.015_bib21","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.21037\/gs-20-335","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer recurrence: systematic review and meta-analysis","volume":"9","author":"Cianci","year":"2020","journal-title":"Gland Surg"},{"issue":"3","key":"10.1016\/j.tjog.2025.05.015_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ygyno.2020.09.022","article-title":"Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States","volume":"159","author":"Charo","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.tjog.2025.05.015_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071266","article-title":"The use of CA-125 KELIM to identify which patients can achieve complete cytoreduction after neoadjuvant chemotherapy in high-grade serous advanced ovarian cancer","volume":"16","author":"Zouzoulas","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925001767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925001767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:18:38Z","timestamp":1757513918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455925001767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1028455925001767"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2025.05.015","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KELIM score and BRCA status are unreliable to predict the completeness of cytoreduction during interval debulking surgery with hyperthermic intraperitoneal chemotherapy for ovarian cancers","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2025.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}